{
    "clinical_study": {
        "@rank": "33478", 
        "arm_group": [
            {
                "arm_group_label": "Arm A: Nivolumab + Ipilimumab and Nivolumab", 
                "arm_group_type": "Experimental", 
                "description": "Part I:\nNivolumab 1 mg/kg solution and Ipilimumab 3 mg/kg solution intravenously every 3 weeks for 4 doses (4 Cycles)\nPart II:\nNivolumab 3 mg/kg solution intravenously every 2 weeks until documented disease progression due to toxicity, withdrawal of consent or the study ends"
            }, 
            {
                "arm_group_label": "Arm B: Nivolumab-placebo + Ipilimumab and Nivolumab-placebo", 
                "arm_group_type": "Experimental", 
                "description": "Part I:\nPlacebo matching with Nivolumab 0 mg/kg solution and Ipilimumab 3 mg/kg solution intravenously every 3 weeks for 4 doses (4 Cycles)\nPart II:\nPlacebo matching with Nivolumab 0 mg/kg solution intravenously every 2 weeks until documented disease progression due to toxicity, withdrawal of consent or the study ends\nAfter documented disease progression, subjects in Arm B will have the option to either start Nivolumab monotherapy on-study (3 mg/kg solution  intravenously  every 2 weeks) or proceed to follow-up phase of the protocol"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary purpose of this study is to compare the objective response rate (ORR) as\n      determined by investigators, of Nivolumab combined with Ipilimumab versus Ipilimumab\n      monotherapy in subjects with unresectable or metastatic melanoma"
        }, 
        "brief_title": "Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma (CheckMate 069)", 
        "completion_date": {
            "#text": "May 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Unresectable or Metastatic Melanoma", 
        "condition_browse": {
            "mesh_term": "Melanoma"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "For more information regarding BMS clinical trial participation, please visit\n        www.BMSStudyConnect.com\n\n        Inclusion Criteria:\n\n          -  Eastern Cooperative Oncology Group (ECOG) performance status (PS) 0 or 1\n\n          -  Histologically confirmed unresectable Stage III or Stage IV melanoma, as per AJCC\n             staging system\n\n          -  No prior systemic anticancer therapy for unresectable or metastatic melanoma. Note\n             that prior adjuvant or neoadjuvant melanoma therapy is permitted if it was completed\n             at least 6 weeks prior to date of first dose, and all related adverse events have\n             either returned to baseline or stabilized\n\n          -  Tumor tissue obtained in the metastatic setting or from an unresectable site must be\n             provided for biomarker analyses. In order to be randomized, tumor tissue should be\n             received by the central laboratory. Biopsy should be excisional, incisional punch or\n             core needle. Fine needle aspirates or other cytology samples are insufficient\n\n          -  Known BRAF V600 mutation status as determined by an FDA approval test. Subjects with\n             either V600 wild-type or V600 mutation-positive melanoma are eligible\n\n        Exclusion Criteria:\n\n          -  Active brain metastases or leptomeningeal metastases. Subjects with brain metastases\n             are eligible if these have been treated and there is no magnetic resonance imaging\n             (MRI) evidence of progression for at least 8 weeks after treatment is complete and\n             within 28 days prior to first dose of study drug administration. There must also be\n             no requirement for high doses of systemic corticosteroids that could result in\n             immunosuppression (>10 mg/day prednisone equivalents) for at least 2 weeks prior to\n             study drug administration\n\n          -  Ocular melanoma\n\n          -  Subjects with active, known or suspected autoimmune disease. Subjects with vitiligo,\n             type I diabetes mellitus, residual hypothyroidism due to autoimmune condition only\n             requiring hormone replacement, psoriasis not requiring systemic treatment, or\n             conditions not expected to recur in the absence of an external trigger are permitted\n             to enroll"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01927419", 
            "org_study_id": "CA209-069", 
            "secondary_id": "2013-002018-11"
        }, 
        "intervention": [
            {
                "arm_group_label": "Arm A: Nivolumab + Ipilimumab and Nivolumab", 
                "intervention_name": "Nivolumab", 
                "intervention_type": "Biological", 
                "other_name": "BMS-936558"
            }, 
            {
                "arm_group_label": [
                    "Arm A: Nivolumab + Ipilimumab and Nivolumab", 
                    "Arm B: Nivolumab-placebo + Ipilimumab and Nivolumab-placebo"
                ], 
                "intervention_name": "Ipilimumab", 
                "intervention_type": "Biological"
            }, 
            {
                "arm_group_label": "Arm B: Nivolumab-placebo + Ipilimumab and Nivolumab-placebo", 
                "intervention_name": "Placebo matching with Nivolumab", 
                "intervention_type": "Biological"
            }
        ], 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 27, 2014", 
        "link": [
            {
                "description": "BMS Clinical Trial Information", 
                "url": "http://ctr.bms.com/ctd/start.do"
            }, 
            {
                "description": "BMS clinical trial educational resource", 
                "url": "http://www.bms.com/studyconnect/Pages/home.aspx"
            }, 
            {
                "description": "Investigator Inquiry form", 
                "url": "http://www.bms.com/clinical_trials/Pages/Investigator_Inquiry_form.aspx"
            }, 
            {
                "description": "FDA Safety Alerts and Recalls", 
                "url": "http://www.fda.gov/MEDWATCH/safety.htm"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "San Francisco", 
                        "country": "United States", 
                        "state": "California", 
                        "zip": "94115"
                    }, 
                    "name": "San Francisco Oncology Associates"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Orlando", 
                        "country": "United States", 
                        "state": "Florida", 
                        "zip": "32806"
                    }, 
                    "name": "Orlando Health Inc"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Louisville", 
                        "country": "United States", 
                        "state": "Kentucky", 
                        "zip": "40202"
                    }, 
                    "name": "James Graham Brown Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Boston", 
                        "country": "United States", 
                        "state": "Massachusetts", 
                        "zip": "02215"
                    }, 
                    "name": "Dana Farber Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "St. Louis", 
                        "country": "United States", 
                        "state": "Missouri", 
                        "zip": "63110"
                    }, 
                    "name": "Washington University School Of Medicine"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Las Vegas", 
                        "country": "United States", 
                        "state": "Nevada", 
                        "zip": "89148"
                    }, 
                    "name": "Comprehensive Cancer Centers Of Nevada"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Lebanon", 
                        "country": "United States", 
                        "state": "New Hampshire", 
                        "zip": "03756"
                    }, 
                    "name": "Dartmouth-Hitchcock Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Albuquerque", 
                        "country": "United States", 
                        "state": "New Mexico", 
                        "zip": "87106"
                    }, 
                    "name": "University Of New Mexico Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10016"
                    }, 
                    "name": "Nyu Clinical Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New York", 
                        "country": "United States", 
                        "state": "New York", 
                        "zip": "10065"
                    }, 
                    "name": "Memorial Sloan Kettering Cancer Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Durham", 
                        "country": "United States", 
                        "state": "North Carolina", 
                        "zip": "27710"
                    }, 
                    "name": "Duke University Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Cincinnati", 
                        "country": "United States", 
                        "state": "Ohio", 
                        "zip": "45219"
                    }, 
                    "name": "The Christ Hospital"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Portland", 
                        "country": "United States", 
                        "state": "Oregon", 
                        "zip": "97239"
                    }, 
                    "name": "Oregon Health & Science University"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Easton", 
                        "country": "United States", 
                        "state": "Pennsylvania", 
                        "zip": "18045"
                    }, 
                    "name": "St Lukes Can Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Greenville", 
                        "country": "United States", 
                        "state": "South Carolina", 
                        "zip": "29615"
                    }, 
                    "name": "Ghs Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Salt Lake City", 
                        "country": "United States", 
                        "state": "Utah", 
                        "zip": "84112"
                    }, 
                    "name": "Huntsman Cancer Institute"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Madison", 
                        "country": "United States", 
                        "state": "Wisconsin", 
                        "zip": "53792"
                    }, 
                    "name": "University Of Wisconsin Hospital And Clinics"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Toulouse", 
                        "country": "France", 
                        "zip": "31059"
                    }, 
                    "name": "Local Institution"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Villejuif", 
                        "country": "France", 
                        "zip": "94805"
                    }, 
                    "name": "Local Institution"
                }
            }
        ], 
        "location_countries": {
            "country": [
                "United States", 
                "France"
            ]
        }, 
        "number_of_arms": "2", 
        "official_title": "Phase 2, Randomized, Double Blinded, Study of Nivolumab (BMS-936558) in Combination With Ipilimumab vs Ipilimumab Alone in Subjects With Previously Untreated, Unresectable or Metastatic Melanoma", 
        "overall_official": {
            "affiliation": "Bristol-Myers Squibb", 
            "last_name": "Bristol-Myers Squibb", 
            "role": "Study Director"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": [
                "United States: Food and Drug Administration", 
                "France: Ministry of Health"
            ], 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "July 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The ORR is defined as the # of subjects with a best overall response (BOR) of complete response (CR) or Partial Response (PR) divided by the number of randomized BRAF wild type (WT) subjects", 
            "measure": "Objective response rate (ORR) as assessed by the investigator", 
            "safety_issue": "No", 
            "time_frame": "Until disease progression is documented (expected to be no more than 5 years)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01927419"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "description": "The PFS is defined as the time between the date of randomization and the first date of documented progression, as assessed by the investigator, or death due to any cause, whichever occurs first", 
                "measure": "Investigator assessed progression free survival (PFS) in BRAF WT subjects", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression is documented (expected to be no more than 5 years)"
            }, 
            {
                "measure": "ORR and PFS in BRAF mutant subjects", 
                "safety_issue": "No", 
                "time_frame": "Until disease progression is documented (expected to be no more than 5 years)"
            }, 
            {
                "description": "EORTC-QLQ-C30 = European Organisation for Research and Treatment of Care\nQoL = Quality of life", 
                "measure": "Mean changes from baseline in the EORTC-QLQ-C30 global health status/QoL composite scale", 
                "safety_issue": "No", 
                "time_frame": "Every 6 weeks for the first 6 months"
            }
        ], 
        "source": "Bristol-Myers Squibb", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Bristol-Myers Squibb", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "August 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}